<DOC>
	<DOCNO>NCT01378286</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate non-inferiority correct adequate clinical parasitological response Day 28 Artesunate Amodiaquine ( ASAQ ) versus chloroquine Secondary Objectives : - To assess non inferiority way main criterion : - Day 28 corrected cure rate - Day 14 Day 42 correct cure rate - To compare two group treatment term : - Efficacy : - Proportion aparasitaemic patient 24 , 48 72 hour - Proportion afebrile patient 24 , 48 72 hour - Percentage gametocyte carrier follow-up - Evolution mean gametocytes 42 day follow-up - Evolution haemoglobin value Day 0 Day 7 , Day 0 Day 28 - Clinical biological tolerability : - Proportion adverse event - Biological safety : haematology ( Red blood cell , Haemoglobin , White Blood Cells , neutrophils , platelet ) , biochemistry ( creatinine , transaminase ( alanine amino transferase/ALT ) , bilirubins ) - ECG ( electro encephalogram ) ( Day 0 , Day 3 , Day 28 ) patient 10 year old</brief_summary>
	<brief_title>Efficacy Tolerability Artesunate Amodiaquine Versus Chloroquine Treatment Uncomplicated Plasmodium Vivax Malaria</brief_title>
	<detailed_description>Each patient follow period 42 day</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Inclusion criterion : Adults child 6 month old bodyweight &gt; 5 kg Able treated oral route Axillary temperature ≥ 37,5 C history fever previous 2 day Symptomatic biologically confirm Plasmodium vivax monoinfection , parasitemia 250 100000 parasite /µl blood Written inform consent patient child write informed consent parents/legal representative child . Children able understand objective risk study sign assent form . Exclusion criterion : Known project leave investigator site area followup period ( 42 day ) Hypersensitivity one investigational medicinal product excipients Intake antimalarial treatment previous 30 day History hepatic ( ) haematological impairment treatment amodiaquine Blurred vision suggest retinopathy Presence least one danger sign malaria Pregnant breastfeed woman Women childbearing potential willing use effective contraceptive method ( ) duration study Known severe concomitant underlying disease The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>